Abstract
Granulocyte-colony stimulating factor (G-CSF) receptor signaling counteracts detrimental pathways in ischemic stroke. In rodents, neuroprotection provided by the G-CSF system involves up-regulation of the G-CSF receptor and its ligand, G-CSF, during cerebral ischemia. The confirmation of a similar response in the human brain would be an important rationale for the use of G-CSF in clinical stroke trials. Therefore, the temporal and cellular profile of G-CSF and G-CSF receptor expression was examined in a series of human stroke brains. The median age of the 21 stroke patients was 67 years; median time from death to autopsy was 24 h (range: 10–67 h). In acute ischemic stroke, strong neuronal G-CSF receptor immunoreactivity was encountered in the infarct area and the peri-infarct rim as compared to the contralateral cortex. In subacute infarctions, microglial and macrophage G-CSF receptor immunoreactivity predominated, whereas chronic infarction was characterized by the presence of G-CSF receptor expressing reactive astrocytes. Neuronal G-CSF expression was encountered very early upon ischemic stroke. At later time-points, an up-regulation of vascular G-CSF expression in the peri-infarct area prevailed. In conclusion, the observed up-regulation of G-CSF receptors and G-CSF points towards a role in the pathophysiology of human ischemic stroke.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484–494
Cervós-Navarro J, Schneider H (1980) (Durchblutungsstörungen und Gefäßerkrankungen des Zentralnervensystems) Durchblutungsstörungen und Gefäßerkrankungen des Zentralnervensystems. Springer, Berlin Heidelberg New York pp 107–119
Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495–505
Gibson CL, Bath PM, Murphy SP (2005) G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 25:431–439
Hasselblatt M, Ehrenreich H, Sirén AL (2006) The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 18:132–138
Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354:2034–2045
Kawada H, Takizawa S, Takanashi T, Morita Y, Fujita J, Fukuda K, Takagi S, Okano H, Ando K, Hotta T (2006) Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 113:701–710
Rogalewski A, Schneider A, Ringelstein EB, Schäbitz WR (2006) Toward a multimodal neuroprotective treatment of stroke. Stroke 37:1129–1136
Schäbitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, Sommer C, Schwab S (2003) Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 34:745–751
Schäbitz WR, Schneider A (2006) Developing granulocyte-colony stimulating factor for the treatment of stroke: current status of clinical trials. Stroke 37:1654
Schneeloch E, Mies G, Busch HJ, Buschmann IR, Hossmann KA (2004) Granulocyte-macrophage colony-stimulating factor-induced arteriogenesis reduces energy failure in hemodynamic stroke. Proc Natl Acad Sci USA 101:12730–12735
Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schäbitz WR (2005) The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115:2083–2098
Schneider A, Kuhn HG, Schäbitz WR (2005) A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4:1753–1757
Sirén AL, Knerlich F, Poser W, Gleiter CH, Brück W, Ehrenreich H (2001) Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl) 101:271–276
Solaroglu I, Cahill J, Jadhav V, Zhang JH (2006) A novel neuroprotectant granulocyte-colony stimulating factor. Stroke 37:1123–1128
Acknowledgment
MH is supported by the fund “Innovative Medical Research” of the University of Münster Medical School (HA 110604).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hasselblatt, M., Jeibmann, A., Riesmeier, B. et al. Granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor expression in human ischemic stroke. Acta Neuropathol 113, 45–51 (2007). https://doi.org/10.1007/s00401-006-0152-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-006-0152-y